Abdullah, H., Mohammed, W., Hasan, A. (2024). Study the impact of the Interlukines and Vit.E in patients with Atopic Eczema in Anbar Governorate. , 18(1), 180-189. doi: 10.37652/juaps.2023.144631.1165
Haneen Ahmed Abdullah; Wajeeh Younis Mohammed; Abdullah Saleh Hasan. "Study the impact of the Interlukines and Vit.E in patients with Atopic Eczema in Anbar Governorate". , 18, 1, 2024, 180-189. doi: 10.37652/juaps.2023.144631.1165
Abdullah, H., Mohammed, W., Hasan, A. (2024). 'Study the impact of the Interlukines and Vit.E in patients with Atopic Eczema in Anbar Governorate', , 18(1), pp. 180-189. doi: 10.37652/juaps.2023.144631.1165
Abdullah, H., Mohammed, W., Hasan, A. Study the impact of the Interlukines and Vit.E in patients with Atopic Eczema in Anbar Governorate. , 2024; 18(1): 180-189. doi: 10.37652/juaps.2023.144631.1165

Study the impact of the Interlukines and Vit.E in patients with Atopic Eczema in Anbar Governorate

Journal of University of Anbar for Pure Science
Volume 18, Issue 1, June 2024, Pages 180-189    PDF (713.24 K)
Document Type: Research Paper
DOI: 10.37652/juaps.2023.144631.1165
Authors
Haneen Ahmed Abdullah* 1; Wajeeh Younis Mohammed2; Abdullah Saleh Hasan3
1Department of Chemistry, College of Science, University of Anbar, Anbar, Iraq
2Department of chemistry college of science Al-anbar University/Al-anbar/Iraq
3Department of Internal Medicine, College of Medicine, Anbar University, Anbar, Iraq
Abstract
Atopic Eczema commonly known as “atopic dermatitis” (AD), is a form of “inflammatory skin condition that impairs the skin” barrier and its capacity to retain moisture, “it is the most prevalent chronic skin condition” and is inherited. “Although AD can affect people of all ages, it most often” first manifests in “infancy and early childhood”. Both its duration and its onset in maturity are possibilities , “Patients are impacted not just by the social” stigma associated “with having a visible skin condition”, but also by the disease's extreme itching, which “frequently causes skin injuries and serious sleep difficulties”. Additionally, “emollients (agents that calm, moisturize, and soften the skin) and topical drugs must be applied often”, and “doctor visits are required for condition” care,
IL-4 has been “shown in mouse models to be both necessary for the genesis” of AD and “capable of inducing all of the disease's histopathological” symptoms , The “overexpression of IL-4 causes IgE production to rise”, skin inflammation to worsen, “bacterial skin infection to be encouraged, and pruritus” to be mediated, Previous “research demonstrated the critical involvement” of IL-13 in the pathogenesis of AD, “particularly with regard to various disease” pathogenesis factors” like disruption of the skin barrier”, thickening of the epidermis, itching, inflammation”, and infection”, Vitamin E acts as an “antioxidant in cell membranes where it stops the spread of free radical” reactions, however research has “also shown that it has pro-oxidant properties”. Most studies have “proven its relationship with the skin”, including atopic dermatitis.
Keywords
atopic dermatitis,,; ,،Interleukin,,; ,،Oxidative stress
References
  • Thomson, J., Wernham, A. G. H., & Williams, H. C. (2018). Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. British Journal of Dermatology, 178(4), 897-902.‏
  • EUROPEAN CONSENSUS REPORT – THE BURDEN OF ATOPIC ECZEMAEdited by: Gary Finnegan, Eleanor Morrissey, Isabel Proaño, Valeria Ramicon 2022.
  • Nutten, S. (2015). Atopic dermatitis: global epidemiology and risk factors. Annals of nutrition and metabolism, 66(Suppl. 1), 8-16.‏
  • Drislane, C., & Irvine, A. D. (2020). The role of filaggrin in atopic dermatitis and allergic disease. Annals of Allergy, Asthma & Immunology, 124(1), 36-43.‏
  • Moosbrugger-Martinz, V., Leprince, C., Méchin, M. C., Simon, M., Blunder, S., Gruber, R., & Dubrac, S. (2022). Revisiting the Roles of Filaggrin in Atopic Dermatitis. International Journal of Molecular Sciences, 23(10), 5318.‏
  • Grafanaki, K., Bania, A., Kaliatsi, E. G., Vryzaki, E., Vasilopoulos, Y., & Georgiou, S. (2023). The Imprint of Exposome on the Development of Atopic Dermatitis across the Lifespan: A Narrative Review. Journal of Clinical Medicine, 12(6), 2180.‏
  • Talamonti, M., Galluzzo, M., Silvaggio, D., Lombardo, P., Tartaglia, C., & Bianchi, L. (2021). Quality of life and psychological impact in patients with atopic dermatitis. Journal of clinical medicine, 10(6), 1298.‏
  • Oykhman, P., Dookie, J., Al-Rammahy, H., De Benedetto, A., Asiniwasis, R. N., LeBovidge, J., ... & Chu, D. K. (2022). Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice.‏
  • Silvestre Salvador, J. F., Romero-Pérez, D., & Encabo-Durán, B. (2017). Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol, 27(2), 78-88.‏
  • Seghers, A. C., Lee, J. S., Tan, C. S., Koh, Y. P., Ho, M. S., Lim, Y. L., ... & Tang, M. B. (2014). Atopic dirty neck or acquired atopic hyperpigmentation? An epidemiological and clinical study from the National Skin Centre in Singapore. Dermatology, 229(3), 174-182.‏
  • David Boothe, W., Tarbox, J. A., & Tarbox, M. B. (2017). Atopic dermatitis: pathophysiology. Management of atopic dermatitis: methods and challenges, 21-37.‏
  • Mizel, S. B. (1989). The interleukins 1. The FASEB journal, 3(12), 2379-2388.‏
  • Mehrbani, S. P., Motahari, P., Azar, F. P., & Ahari, M. A. (2020). Role of interleukin-4 in pathogenesis of oral lichen planus: A systematic review. Medicina oral, patologia oral y cirugia bucal, 25(3), e410.‏
  • Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., ... & Radin, A. R. (2014). Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New England Journal of Medicine, 371(2), 130-139.‏
  • Shin, K. O., Ha, D. H., Kim, J. O., Crumrine, D. A., Meyer, J. M., Wakefield, J. S., ... & Cho, B. S. (2020). Exosomes from human adipose tissue-derived mesenchymal stem cells promote epidermal barrier repair by inducing de novo synthesis of ceramides in atopic dermatitis. Cells, 9(3), 680.‏
  • Mennini, M., Dahdah, L., & Fiocchi, A. (2017). Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 376(11), 1090.‏
  • Tsoi, L. C., Rodriguez, E., Stölzl, D., Wehkamp, U., Sun, J., Gerdes, S., ... & Weidinger, S. (2020). Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. Journal of Allergy and Clinical Immunology, 145(5), 1406-1415.‏
  • Jin, J., Sunusi, S., & Lu, H. (2022). Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target. Journal of International Medical Research, 50(1), 03000605211053156.‏
  • Tubau, C., & Puig, L. (2021). Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Review of Clinical Immunology, 17(1), 15-25.‏
  • Gandhi, N. A., Bennett, B. L., Graham, N. M., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016). Targeting key proximal drivers of type 2 inflammation in disease. Nature reviews Drug discovery, 15(1), 35-50.‏
  • Napolitano, M., di Vico, F., Ruggiero, A., Fabbrocini, G., & Patruno, C. (2023). The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. Frontiers in Medicine, 10, 745.‏
  • Maintz, L., Welchowski, T., Herrmann, N., Brauer, J., Traidl‐Hoffmann, C., Havenith, R., ... & Reiger, M. (2023). IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis. Allergy.‏
  • Ratnarajah, K., Le, M., Muntyanu, A., Mathieu, S., Nigen, S., Litvinov, I. V., ... & Netchiporouk, E. (2021). Inhibition of IL-13: a new pathway for atopic dermatitis. Journal of Cutaneous Medicine and Surgery, 25(3), 315-328.‏
  • Moyle, M., Cevikbas, F., Harden, J. L., & Guttman‐Yassky, E. (2019). Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Experimental dermatology, 28(7), 756-768.
  • Moriguchi, S., & Muraga, M. (2000). Vitamin E and immunity.‏
  • Herrera, E., & Barbas, C. (2001). Vitamin E: action, metabolism and perspectives. Journal of physiology and biochemistry, 57, 43-56.‏
  • Shadisvaaran, S., Chin, K. Y., Shahida, M. S., Ima-Nirwana, S., & Leong, X. F. (2021). Effect of vitamin E on periodontitis: Evidence and proposed mechanisms of action. Journal of oral biosciences, 63(2), 97-103.‏
  • Zingg, J. M. (2015). Vitamin E: a role in signal transduction. Annual review of nutrition, 35, 135-173.‏
  • Shahidi, F., Pinaffi-Langley, A. C. C., Fuentes, J., Speisky, H., & de Camargo, A. C. (2021). Vitamin E as an essential micronutrient for human health: Common, novel, and unexplored dietary sources. Free Radical Biology and Medicine, 176, 312-321.‏
  • Pekmezci, D. (2011). Vitamin E and immunity. Vitamins & hormones, 86, 179-215.‏
  • Kelly-Welch, A. E., Hanson, E. M., Boothby, M. R., & Keegan, A. D. (2003). Interleukin-4 and interleukin-13 signaling connections maps. Science, 300(5625), 1527-1528.‏
  • Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999). The IL-4 receptor: signaling mechanisms and biologic functions. Annual review of immunology, 17(1), 701-738.‏
  • Wynn, T. A. (2003). IL-13 effector functions. Annual review of immunology, 21(1), 425-456.‏
  • Kaminishi, K., Soma, Y., Kawa, Y., & Mizoguchi, M. (2002). Flow cytometric analysis of IL-4, IL-13 and IFN-γ expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. Journal of dermatological science, 29(1), 19-25.‏
  • Bodoor, K., Al-Qarqaz, F., Heis, L. A., Alfaqih, M. A., Oweis, A. O., Almomani, R., & Obeidat, M. A. (2020). IL-33/13 axis and IL-4/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis. Clinical, cosmetic and investigational dermatology, 419-424.‏
  • Totsuka, A., Omori-Miyake, M., Kawashima, M., Yagi, J., & Tsunemi, Y. (2017). Expression of keratin 1, keratin 10, desmoglein 1 and desmocollin 1 in the epidermis: possible downregulation by interleukin-4 and interleukin-13 in atopic dermatitis. European Journal of Dermatology, 27, 247-253.‏
  • Marone, G., Granata, F., Pucino, V., Pecoraro, A., Heffler, E., Loffredo, S., ... & Varricchi, G. (2019). The intriguing role of interleukin 13 in the pathophysiology of asthma. Frontiers in pharmacology, 10, 1387.‏
  • Doran, E., Cai, F., Holweg, C. T., Wong, K., Brumm, J., & Arron, J. R. (2017). Interleukin-13 in asthma and other eosinophilic disorders. Frontiers in medicine, 4, 139.‏
  • Mao, Y. M., Zhao, C. N., Leng, J., Leng, R. X., Ye, D. Q., Zheng, S. G., & Pan, H. F. (2019). Interleukin-13: A promising therapeutic target for autoimmune disease. Cytokine & growth factor reviews, 45, 9-23.‏
  • Gonçalves, F., Freitas, E., & Torres, T. (2021). Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs in context, 10.‏
  • Furue, M. (2020). Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. International journal of molecular sciences, 21(15), 5382.‏
  • Ungar, B., Garcet, S., Gonzalez, J., Dhingra, N., da Rosa, J. C., Shemer, A., ... & Guttman-Yassky, E. (2017). An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. Journal of Investigative Dermatology, 137(3), 603-613.‏
  • Teo, C. W. L., Tay, S. H. Y., Tey, H. L., Ung, Y. W., & Yap, W. N. (2021). Vitamin E in atopic dermatitis: from preclinical to clinical studies. Dermatology, 237(4), 553-564.‏
  • Kato, E., & Takahashi, N. (2012). Improvement by sodium dl-α-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels. Bioorganic & medicinal chemistry, 20(12), 3837-3842.‏
  • Hayashi, D., Sugaya, H., Ohkoshi, T., Sekizawa, K., Takatsu, H., Shinkai, T., & Urano, S. (2012). Vitamin E improves biochemical indices associated with symptoms of atopic dermatitis-like inflammation in NC/Nga mice. Journal of nutritional science and vitaminology, 58(3), 161-168.‏
  • Reynolds, K. A., Juhasz, M. L., & Mesinkovska, N. A. (2019). The role of oral vitamins and supplements in the management of atopic dermatitis: a systematic review. International journal of dermatology, 58(12), 1371-1376.‏
  • Vaughn, A. R., Foolad, N., Maarouf, M., Tran, K. A., & Shi, V. Y. (2019). Micronutrients in atopic dermatitis: a systematic review. The Journal of Alternative and Complementary Medicine, 25(6), 567-577.‏
Statistics
Article View: 1,012
PDF Download: 220


Journal Management System. Powered by iJournalPro.com